Previous close | 0.5800 |
Open | 0.5800 |
Bid | 0.5700 x 1566800 |
Ask | 0.5750 x 380500 |
Day's range | 0.5700 - 0.5850 |
52-week range | 0.5700 - 1.3900 |
Volume | |
Avg. volume | 405,244 |
Market cap | 269.38M |
Beta (5Y monthly) | 0.28 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.4900 |
Earnings date | 27 Aug 2023 - 31 Aug 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 11 Oct 2004 |
1y target est | 7.01 |
MELBOURNE, Australia, May 25, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company’s Chief Executive Officer will present at the Jefferies Healthcare Conference being held at the Marriott Marquis in New York City on June 7-9 2023. Dr. Baldwin will present on Wednesday, June 7th at 2:00 – 2:25 PM EST (4:00 A
Key Insights The considerable ownership by individual investors in Opthea indicates that they collectively have a...
MELBOURNE, Australia, May 17, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Elemer Piros, Senior Biotechnlogy Analyst at EF Hutton will host a webinar with Dr. Megan Baldwin, CEO and Managing Director and Timothy E. Morris, CFO of Opthea Limited on Thursday, May 18th at 5:00 pm EDT (Friday, May 19th at 7:00 am AEST). Participates
MELBOURNE, Australia, May 08, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Timothy E. Morris, the Company’s Chief Financial Officer will present at the JMP Securities Life Sciences Conference being held in New York City on May 15-16 2023. Mr.Morris will present on Tuesday, May 16th at 1:00 pm ET (3:00 am May 17th AEDT), which can
MELBOURNE, Australia, April 28, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that management will participate in the one-on-one meeting portion of the H.C. Wainwright BioConnect Conference being held on May 2, 2023. The Conference is produced in partnership with NASDAQ and will take place at the exchange’s world headquarters in New Yo
MELBOURNE, Australia, March 07, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that it has received an A$8.7 million (US$6.3 million) research and development (R&D) tax credit from the Australian Taxation Office. The cash incentive is for research and development costs incurred in the 2021/2022 financial year, and represents the amount
MELBOURNE, Australia, March 06, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company’s Chief Executive Officer, will participate in a fireside chat at Oppenheimer’s 33rd Annual Healthcare Conference being held virtually on March 13-15, 2023. Dr. Baldwin’s conversation with Hartaj Singh, Managing Director an
Opthea ( ASX:OPT ) First Half 2023 Results Key Financial Results Net loss: US$77.1m (loss widened by 104% from 1H...
MELBOURNE, Australia, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that the Phase 2b study results of OPT-302, the Company’s anti-VEGF-C/-D “trap” agent administered in combination with Lucentis® (ranibizumab) for the treatment of wet age-related macular degeneration (AMD), have been published online in Ophthalmology, the jou
MELBOURNE, Australia, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company’s Chief Executive Officer will present at SVB Leerink’s Global Biopharma Conference being held virtually on February 14-16, 2023. Dr. Baldwin’s presentation will take place on Wednesday February 15th at 5:00 pm ET (9:00 am A
MELBOURNE, Australia, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company’s Chief Executive Officer will present at the Sequire Biotechnology Conference being held virtually on February 2, 2023. Dr. Baldwin will present on Thursday, February 2nd at 10:00 am ET (2:00 am AEDT). To access the present
MELBOURNE, Australia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announce that MST Access will host an “Ask the Expert” conference call with Professor Jason S. Slakter, M.D. on Tuesday 13th December 6:30pm – 7:30pm EST USA (Wednesday 14th December 10:30am – 11:30am AEDT). Prof Slakter is a board certified Retinal and Macular Disease Specia
Every investor in Opthea Limited ( ASX:OPT ) should be aware of the most powerful shareholder groups. And the group...
MELBOURNE, Australia, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announce a podium talk will be presented at the annual FLORetina congress, taking place in Rome, Italy from December 8-11, 2022. Dr. Caroline Baumal, MD from the Tufts University School of Medicine, New England Eye Center, Boston, Massachusetts will present on OPT-302 combina
MELBOURNE, Australia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced that Chief Executive Officer Dr. Megan Baldwin will present at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022 at 7:25 AM GMT (6:25 PM AEDT). The live audio will be webcast and may be accessed for 90 days on the Investors page of the O
Key appointment as Opthea progresses Phase 3 registrational trials of OPT-302 for wet AMD MELBOURNE, Australia, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, is pleased to announce the appointment of Timothy E. Morris as Chief Financial Officer (CFO), effective 24 October 2022. Mr. Morris is a veteran pharmaceutical executive based in the U.S
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Secured up to US$170m in non-dilutive financing Received commitments for well supported US$90m equity financing; closed first tranche for US$41.9 million Expanded management team and US operations with appointment of C-Suite Executives Elected Mr. Quinton Oswald and Dr. Susan Orr to Board of Directors MELBOURNE, Australia, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and pro
MELBOURNE, Australia, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that Chief Executive Officer Dr. Megan Baldwin will present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference, taking place virtually on August 17, 2022. The presentation will be made available at 7:00 AM ET (9:00 PM AET) and may be accessed for 90
MELBOURNE, Australia, Aug. 14, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ: OPT) (Opthea), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, is pleased to confirm it has received binding commitments for a successful two-tranche placement (Placement) of new fully paid ordinary shares (New Shares) to institutional investors to raise approximately US$90 million1 (A$128.57 million) at a price of A$1.15 per N
Carlyle and its life sciences franchise Abingworth, working with their recently formed development company Launch Therapeutics (Launch Tx), to provide non-dilutive financing of up to US$170M, consisting of a US$120M commitment and an option to increase funding by a further US$50MIf OPT-302 is approved in a major market, Carlyle and Abingworth will be eligible to receive fixed success payments and variable success payments of 7% on annual net sales, which terminate after reaching four times the f
Every investor in Opthea Limited ( ASX:OPT ) should be aware of the most powerful shareholder groups. Large companies...